Articles tagged "Hepatocellular carcinoma"

2020 American Transplant Congress
Efficacy of Radiofrequency Ablation in the Treatment of Patients with Hepatocellular Carcinoma and Compensated Liver Disease: A Pathological Evaluation of Liver Explants
W. Alhamoudi¹, I. Salih², S. Yousif², M. Shawkat³, K. Bzeizi², A. Albenmousa², S. Alghamdi², M. Sturdevant², D. Broering², H. Alsuhaibani²
¹Medicine, King Saud University, Riyadh, Saudi Arabia, ²Liver Transplant, King Faisal Specialist Hospital, Riyadh, Saudi Arabia, ³Internal Medicine, Minia University, Minia, Egypt
*Purpose: Radiofrequency ablation (RFA) is a safe and effective treatment for patients with limited hepatocellular carcinoma (HCC). Ablative outcomes have been largely based on radiological…
2020 American Transplant Congress
Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) recurrence after transplantation is associated with higher tumor grade on explant, failure to respond to DEB-TACE, and pretreatment lymphopenia. We prospectively…
2020 American Transplant Congress
Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation
M. Najjar¹, K. Halazun², M. Mondal¹, A. Srivastava¹, M. Moore¹, E. Rizk¹, R. Gartrell¹, H. Remotti¹, L. Fazlollahi¹, E. Verna¹, A. Griesemer¹, A. Mathur¹, B. Samstein², J. Emond¹, Y. Saenger¹
¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: Peritumoral neutrophil (PMN) infiltration has been associated with poor clinical outcomes in various tumors; however, its role in hepatocellular carcinoma (HCC) remains understudied. Moreover,…
2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
K. Nunez, T. Sandow, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
2020 American Transplant Congress
Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy
A. Mathur, E. Baughan, A. Griesemer, M. Najjar, O. Perez, A. Qian, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…
2020 American Transplant Congress
The Perioperative Coagulation Profile of Hepatocellular Carcinoma During Liver Transplantation Compared to Patients with Non-Malignant Disease: A Cause or Association for Decreased Blood Product Utilization During Liver Transplantation?
H. B. Moore, E. Pomfret, J. Pomposelli, C. Walker, R. Choudhury, H. Yaffe, M. Wachs, T. Bak, K. Conzen, M. Adams, T. Pshak, T. L. Nydam
University of Colorado, Aurora, CO
*Purpose: Hepatobiliary malignancies have been associated with hyper-coagulability. However, the impact of hepatocellular carcinoma (HCC) on coagulation during liver transplantation remains less clear. We hypothesize…
2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
T. Kitajima¹, S. Nagai¹, D. Moonka², S. Yeddula¹, O. Rizzo¹, M. Kavousi¹, R. Salgia², M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…
2020 American Transplant Congress
Waiting List Mortality of Liver Tumors
V. G. Menon, Y. Chen, D. C. Chang, H. Yeh
Division of Transplantation, Massachusetts General Hospital, Boston, MA
*Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics
C. Durkin¹, D. E. Kaplan², T. Bittermann²
¹Internal Medicine, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology, University of Pennsylvania, Philadelphia, PA
*Purpose: A United Network for Organ Sharing (UNOS) policy change in 2015 created a 6-month delay in the receipt of T2 hepatocellular carcinoma (HCC) exception…

« Previous Page
1
…
6
7
8
9
10
…
23
Next Page »